Exicure, Inc. Announces Director Departure and Election

Ticker: XCUR · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1698530

Exicure, Inc. 8-K Filing Summary
FieldDetail
CompanyExicure, Inc. (XCUR)
Form Type8-K
Filed DateJan 6, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $8.7 million
Sentimentneutral

Sentiment: neutral

Topics: director-change, officer-compensation

TL;DR

Exicure's board is changing: Walt out, Davies in. Officer pay also adjusted.

AI Summary

On January 1, 2025, Exicure, Inc. filed an 8-K report detailing the departure of Director Dr. David R. Walt and the election of Dr. Robert J. T. H. Davies as a new director. The company also announced changes to its compensatory arrangements for certain officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes and adjustments to executive compensation can introduce uncertainty regarding future strategic direction and leadership stability.

Key Players & Entities

  • Exicure, Inc. (company) — Registrant
  • Dr. David R. Walt (person) — Departing Director
  • Dr. Robert J. T. H. Davies (person) — Newly Elected Director
  • January 1, 2025 (date) — Date of earliest event reported

FAQ

Who is Dr. David R. Walt and why did he depart from Exicure, Inc.'s board?

Dr. David R. Walt was a Director of Exicure, Inc. The filing indicates his departure but does not specify the reason.

Who is Dr. Robert J. T. H. Davies and what is his role at Exicure, Inc.?

Dr. Robert J. T. H. Davies has been elected as a new Director of Exicure, Inc., effective January 1, 2025.

What other significant events are reported in this 8-K filing?

Besides the director changes, the filing also reports on changes to the compensatory arrangements of certain officers of Exicure, Inc.

When was this 8-K report filed with the SEC?

This 8-K report was filed with the SEC on January 6, 2025.

What is Exicure, Inc.'s principal executive office address?

Exicure, Inc.'s principal executive offices are located at 2430 N. Halsted St., Chicago, IL 60614.

Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-06 16:55:42

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share XCUR The Nasdaq Stock Market
  • $8.7 million — mber 24, 2024, the Company received the $8.7 million in connection with the closing of the C

Filing Documents

02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Appointment of Audit Committee Members As previously disclosed on December 17, 2024, Exicure, Inc. (the "Company") announced the appointment of Chang Keun Choi and Minwoo Kang to the Company's Board of Directors (the "Board"), effective December 19, 2024. Furthermore, effective January 1, 2005, Mr. Choi and Mr. Kang have been appointed to the Audit Committee of the Board, with Mr. Kang serving as the Chair of the Audit Committee.

01 Other Events

Item 8.01 Other Events On December 24, 2024, the Company received the $8.7 million in connection with the closing of the Common Stock Purchase Agreement between the Company and HiTron Systems Inc. This disclosure serves to inform stakeholders of these recent developments. Further updates will be provided as necessary.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (Embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 EXICURE, INC. (registrant) By: /s/ Andy Yoo Andy Yoo Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.